<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04186442</url>
  </required_header>
  <id_info>
    <org_study_id>HG-BOTOAB-PI-01</org_study_id>
    <nct_id>NCT04186442</nct_id>
  </id_info>
  <brief_title>Evaluate the Safety and Efficacy of Botulax® Versus Botox® in Patient With Overactive Bladder</brief_title>
  <official_title>A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase I Clinical Trial to Compare the Safety and Efficacy of Botulax® Versus Botox® in Patient With Overactive Bladder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hugel</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hugel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the efficacy and safety of Botulax® in treatment of Overactive Bladder&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase I Clinical Trial&#xD;
      to Compare the Safety and Efficacy of Botulax® versus Botox® in Patient with Overactive&#xD;
      Bladder&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 28, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse event incidence rates</measure>
    <time_frame>12 weeks (during the clinical trial)</time_frame>
    <description>To assess severity and frequency of reported TEAE (treatment-emergent adverse event), ADR (adverse drug reaction), and SAE (serious adverse event) after investigational product injection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urinary incontinence rate</measure>
    <time_frame>Baseline to Week 2, Week 6, Week 12</time_frame>
    <description>The change in the average number of Urinary incontinence per day at 2, 6 and 12 weeks from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Voiding frequency rate</measure>
    <time_frame>Baseline to Week 2, Week 6, Week 12</time_frame>
    <description>The change in the average number of voiding frequency per day at 2, 6 and 12 weeks from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary urgency rate</measure>
    <time_frame>Baseline to Week 2, Week 6, Week 12</time_frame>
    <description>The change in the average number of urinary urgency (Urgency Rating Scale; URS≥2)per day at 2, 6 and 12 weeks from baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>Botulinum toxin type A (Botulax®)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Botulinum toxin type A (Botox®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum toxin type A injection</intervention_name>
    <description>Experimental</description>
    <arm_group_label>Botulinum toxin type A (Botulax®)</arm_group_label>
    <other_name>Botulax®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum Toxin Type A Injection [Botox]</intervention_name>
    <description>Active Comparator</description>
    <arm_group_label>Botulinum toxin type A (Botox®)</arm_group_label>
    <other_name>Botox®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female at the age of 19 or older&#xD;
&#xD;
          2. Subjects who agree to participate in the clinical study and voluntarily sign the&#xD;
             written informed consent form&#xD;
&#xD;
          3. Subjects with idiopathic overactive bladder who meets the following conditions:&#xD;
&#xD;
               1. Subjects with persistent overactive bladder symptoms for the last 12 weeks&#xD;
&#xD;
               2. Subjects who are not properly controlled by the administration of anticholinergic&#xD;
                  agents for 4 weeks or more or who are difficult to treat due to adverse reactions&#xD;
&#xD;
               3. Subjects with urinary incontinence, urgency, and urinary frequency symptoms&#xD;
&#xD;
          4. Subjects who are willing to perform clean intermittent catheterization (CIC), if&#xD;
             needed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects who are eligible for any of the following conditions may not participate in this&#xD;
        study:&#xD;
&#xD;
          1. Subjects with the following comorbidities:&#xD;
&#xD;
               1. Subjects with peripheral motor neuron disease (eg. amyotrophic lateral sclerosis,&#xD;
                  motor neuropathy) or systemic neuromuscular junction disorders (eg. myasthenia&#xD;
                  gravis, Lambert-Eaton syndrome)&#xD;
&#xD;
               2. Overactive bladder patients due to neurological factors (eg stroke, spinal cord&#xD;
                  disease, Parkinson's disease, etc.)&#xD;
&#xD;
               3. Subjects with clinically significant stress incontinence&#xD;
&#xD;
               4. Subjects with Urinary Tract Infections*&#xD;
&#xD;
                  * Culture showing ≥10^5 colony-forming units (CFU)/mL and leukocytes ≥5 high&#xD;
                  power field (HPF)&#xD;
&#xD;
               5. Patients with acute urinary retention, or with a history or accompanying diseases&#xD;
                  that can cause urinary retention (urolithiasis, acute cystitis, foreign body in&#xD;
                  the bladder, bladder flow, etc.)&#xD;
&#xD;
               6. Uncontrolled diabetes patients who meet one or more of the following criteria:&#xD;
&#xD;
                    -  HbA1c ≥ 9% at screening&#xD;
&#xD;
                    -  Patients with over 10 years of diabetes&#xD;
&#xD;
                    -  Have diabetic chronic complications (eg diabetic neuropathy, diabetic&#xD;
                       nephropathy, diabetic retinopathy, etc.)&#xD;
&#xD;
                    -  Patients taking a drug that causes glycosuria (sodium-glucose co-transporter&#xD;
                       2 inhibitor, SGLT2 inhibitor)&#xD;
&#xD;
          2. Those who have had lower urinary tract surgery within 24 weeks before screening&#xD;
&#xD;
          3. Those who received botulinum toxin due to urinary system disease within 24 weeks&#xD;
             before screening&#xD;
&#xD;
          4. Those who have been administered botulinum toxin type A within 12 weeks prior to&#xD;
             screening or botulinum toxin type B within 16 weeks of treatment, or planned during&#xD;
             the clinical trials&#xD;
&#xD;
          5. Those who have received or plan to receive oral medications for overactive bladder&#xD;
             including anticholinergic drugs within 1 week prior to randomization&#xD;
&#xD;
          6. Those who received antiplatelet and anticoagulants within 1 week prior to&#xD;
             randomization&#xD;
&#xD;
          7. Subjects with a history of hypersensitivity reactions to any of the components of the&#xD;
             investigational product&#xD;
&#xD;
          8. Women of childbearing potential who are planning to become pregnant during the&#xD;
             clinical trials or are not using an appropriate method of contraception&#xD;
&#xD;
          9. Those who participated in another clinical trial within 12 weeks prior to screening&#xD;
             and received investigational product/medical device/medical procedure&#xD;
&#xD;
         10. Those who are sensitive to cephalosporin or penicillin antibiotics&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jin-Hong Park</last_name>
    <phone>82-2-6966-1651</phone>
    <email>jhpark@hugel.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hugel</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>06162</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 2, 2019</study_first_submitted>
  <study_first_submitted_qc>December 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2019</study_first_posted>
  <last_update_submitted>December 3, 2019</last_update_submitted>
  <last_update_submitted_qc>December 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

